Recent news highlights Curanex's completion of GMP pilot manufacturing for Phyto-N and its targeting of IND submission for ulcerative colitis, marking key steps in clinical development.

• Curanex completed GMP pilot manufacturing for its lead botanical drug candidate Phyto-N and is targeting IND submission for ulcerative colitis as of February 2026 [N1].

Curanex has advanced its lead product candidate Phyto-N through GMP pilot manufacturing and is targeting IND submission for ulcerative colitis, indicating progress in clinical development. The company’s focus on botanical drugs addresses a niche with few FDA-approved products, potentially offering differentiation. Strong liquidity as of end 2025 supports near-term development activities. The acquisition of intellectual property and filing of a PCT application may provide a foundation for market exclusivity if patents are granted. The company’s public status enables access to capital markets for funding development.

Curanex is an early-stage pharmaceutical company with no commercial products or revenues and a history of net losses. The development of botanical drugs involves complex regulatory and manufacturing challenges, with only a few FDA approvals to date. The company faces significant risks including the need for substantial additional capital, uncertainties in obtaining and maintaining patent protection, reliance on third-party manufacturers, and the inherent high failure rate of clinical trials. Failure to raise capital or achieve regulatory milestones could materially impair operations. The company’s limited operating history and small scale add to execution risks.

Curanex's moat is primarily based on its proprietary botanical drug candidate Phyto-N and associated intellectual property rights. The company has acquired provisional patents and filed a PCT application to secure broader patent protection. However, botanical drug development faces unique challenges including complex composition, regulatory hurdles, and patent uncertainties. The company’s early-stage status and reliance on third-party manufacturing limit operational control. The moat is contingent on successful clinical development, regulatory approval, and effective patent protection.

• Capital Requirements and Financing Risk: Curanex requires significant additional capital to fund clinical development and commercialization. Failure to raise sufficient funds could force reduction or discontinuation of operations.
• Clinical Development Risk: Phyto-N is in early development with inherent risks of clinical trial failure, delays, or regulatory rejection, which could impair commercial prospects.
• Intellectual Property Risk: Uncertainty exists regarding successful patent registration and protection of Phyto-N, which could diminish competitive advantage and require costly litigation.
• Manufacturing and Supply Risk: The company relies on third-party manufacturers for clinical drug supplies, exposing it to risks of supply disruption, delays, or unfavorable terms.
• Operational and Management Risk: Limited operating history and small scale may constrain the company’s ability to manage growth, comply with public company requirements, and execute its business plan effectively.

• Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company focused on developing Phyto-N, a botanical drug candidate for ulcerative colitis and other indications.
• The company discontinued sales of health and dietary supplements in 2023 to focus on Phyto-N development.
• Phyto-N is in early preclinical to early clinical development stages, with plans to conduct FDA-required GLP toxicology and pharmacokinetic studies, manufacture clinical trial material, and initiate Phase I clinical trials.
• The company completed a GMP pilot for Phyto-N and targets IND submission for ulcerative colitis as of early 2026.
• Curanex has no commercial products and does not generate revenue from product sales or other commercial activities.
• The company estimates that over $150 million will be required to execute its full business plan through FDA approval and product launch, including Phase II and III trials.
• Curanex expects to finance development through equity offerings, debt financings, strategic partnerships, and grants, but there is no assurance of obtaining sufficient capital.
• The company has incurred net losses and negative cash flows from operations, with a net loss of approximately $4.2 million and basic/diluted EPS of -$0.17 for the fiscal year ended December 31, 2025.
• As of December 31, 2025, Curanex had $5 million in cash and cash equivalents, current assets of approximately $11.2 million, and current liabilities of about $137,000, resulting in a very strong current ratio of 81.93 and cash ratio of 36.49.
• Curanex acquired intellectual property assets from Duraviva, including four provisional patent applications related to Phyto-N, which expired in March 2025.
• The company filed an international PCT application in March 2025 to convert three provisional patents into a utility patent for broader protection, but there is no assurance of successful patent registration.
• Curanex faces risks related to patent protection, clinical trial success, reliance on third-party manufacturers, and the need to raise additional capital to continue operations.
• The company relies on third parties for manufacturing clinical drug supplies and has no internal manufacturing capability.
• Curanex became a public SEC reporting company after its IPO and incurs costs related to compliance with financial reporting and legal requirements.
• The CEO, Jun Liu, has an employment agreement effective March 1, 2026, with defined compensation and responsibilities.
• The company completed repayment of outstanding promissory notes in 2025, eliminating debt and related interest charges.
• The FDA has approved only a few botanical drugs to date, and botanical drug development involves unique challenges including complex composition, standardization, and regulatory hurdles.
• Recent news reports confirm completion of GMP pilot for Phyto-N and targeting IND submission for ulcerative colitis as of February 2026.